Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
Professor Jae-Byum Chang and Professor Yeon Sik Jung's joint research team of the Department of Materials Science and ...
Respiratory illnesses are on the rise across San Antonio, Bexar County and Texas. Doctor Jason Bowling, a professor and infectious diseases specialist at UT Health San Antonio and the Chief ...
The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.
Researchers at the University of Gothenburg, Sweden, in collaboration with colleagues in China, have discovered an ...
The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantically.Recently ...
Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
Alchemab Therapeutics, a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies ...
Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.
Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The ...
Oxford, UK and San Jose, California, 9 January 2024 - (OBT), a clinical stage oncology company with a pipeline of ...
Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback